[{"address1": "4960 Peachtree Industrial Boulevard", "address2": "Suite 240", "city": "Norcross", "state": "GA", "zip": "30071", "country": "United States", "phone": "678 620 3186", "website": "https://galectintherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.", "fullTimeEmployees": 15, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jack W. Callicutt CPA", "age": 57, "title": "CFO, Treasurer & Corporate Secretary", "yearBorn": 1967, "fiscalYear": 2016, "totalPay": 572205, "exercisedValue": 0, "unexercisedValue": 9000}, {"maxAge": 1, "name": "Ms. Beth  Knowles", "title": "Executive Assistant & Officer Manager", "fiscalYear": 2016, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 7, "shareHolderRightsRisk": 3, "overallRisk": 5, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1483142400, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.28, "open": 1.19, "dayLow": 1.15, "dayHigh": 1.32, "regularMarketPreviousClose": 1.28, "regularMarketOpen": 1.19, "regularMarketDayLow": 1.15, "regularMarketDayHigh": 1.32, "payoutRatio": 0.0, "beta": 0.789, "forwardPE": -0.7857143, "volume": 256852, "regularMarketVolume": 250733, "averageVolume": 280659, "averageVolume10days": 255890, "averageDailyVolume10Day": 255890, "bid": 0.9432, "ask": 1.48, "bidSize": 1, "askSize": 2, "marketCap": 83398264, "fiftyTwoWeekLow": 0.73, "fiftyTwoWeekHigh": 4.27, "fiftyDayAverage": 1.454, "twoHundredDayAverage": 2.0901, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 176746256, "profitMargins": 0.0, "floatShares": 44384927, "sharesOutstanding": 63180500, "sharesShort": 8154175, "sharesShortPriorMonth": 7723114, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.1291, "heldPercentInsiders": 0.30489, "heldPercentInstitutions": 0.16024, "shortRatio": 33.49, "shortPercentOfFloat": 0.2168, "impliedSharesOutstanding": 63180500, "bookValue": -1.667, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -47200000, "trailingEps": -0.76, "forwardEps": -1.68, "lastSplitFactor": "1:6", "lastSplitDate": 1332460800, "52WeekChange": -0.64705884, "SandP52WeekChange": -0.024663687, "quoteType": "EQUITY", "currentPrice": 1.32, "recommendationMean": 3.0, "recommendationKey": "hold", "totalCash": 15120000, "totalCashPerShare": 0.239, "totalDebt": 106245000, "quickRatio": 0.427, "currentRatio": 0.487, "returnOnAssets": -1.16077, "freeCashflow": -28938124, "operatingCashflow": -41767000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "GALT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1743799299, "regularMarketTime": 1743796802, "exchange": "NCM", "messageBoardId": "finmb_1065415", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 3.1250064, "regularMarketPrice": 1.32, "shortName": "Galectin Therapeutics Inc.", "longName": "Galectin Therapeutics Inc.", "earningsTimestamp": 1743422401, "earningsTimestampStart": 1747139400, "earningsTimestampEnd": 1747657800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.76, "epsForward": -1.68, "fiftyDayAverageChange": -0.13399994, "fiftyDayAverageChangePercent": -0.092159525, "twoHundredDayAverageChange": -0.7701, "twoHundredDayAverageChangePercent": -0.36845127, "priceToBook": -0.7918416, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Galectin Therapeutics, Inc.", "nameChangeDate": "2025-04-02", "averageAnalystRating": "3.0 - Hold", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1031146200000, "postMarketChangePercent": 2.27273, "postMarketPrice": 1.35, "postMarketChange": 0.03, "regularMarketChange": 0.04000008, "regularMarketDayRange": "1.15 - 1.32", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 280659, "fiftyTwoWeekLowChange": 0.59000003, "fiftyTwoWeekLowChangePercent": 0.8082192, "fiftyTwoWeekRange": "0.73 - 4.27", "fiftyTwoWeekHighChange": -2.9499998, "fiftyTwoWeekHighChangePercent": -0.6908665, "fiftyTwoWeekChangePercent": -64.70589, "displayName": "Galectin Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-04-05"}]